Korea Bolsters Stem Cell Rules, Allows Broader Gene Therapy
This article was originally published in PharmAsia News
South Korea revised a set of rules in December to beef up its regulation of the stem cell and gene therapy sectors, which are seen as part of the country's new growth engines. Under the changes, the government will require stem cell therapy companies to submit risk management plans when they seek product approvals and will introduce a long-term tracking system. The scope of allowable gene therapy research will also be broadened following industry calls.
You may also be interested in...
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
With multiple South Korean INDs to begin Phase III trials with its SGLT-2 inhibitor enavogliflozin, Daewoong is aiming to speed domestic and global development of the potentially best-in-class drug for type 2 diabetes.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.